Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

PUMA BIOTECHNOLOGY INC (PBYI)

Pharmaceutical Preparations

http://www.pumabiotechnology.com

Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.

10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/21/2012

Market Cap

131,690,390

Shares Outstanding

47,570,000

Weighted SO

47,571,332

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

RARE --.--%

CRNX --.--%

ARVN --.--%

RVMD --.--%

KURA --.--%

TSVT --.--%

ICPT --.--%

IOVA --.--%

SRPT --.--%

Beta

1.0730

Last Div

0.0000

Range

2.13-7.73

Chg

0.0350

Avg Vol

500711

Mkt Cap

131690390

Exch

NASDAQ

Country

US

Phone

424 248 6500

DCF Diff

2.8169

DCF

-0.1469

Div Yield

0.0000

P/S

0.6009

EV Multiple

5.1197

P/FV

2.6730

Div Yield %

0.0000

P/E

14.8699

PEG

0.0069

Payout

0.0000

Current Ratio

1.3205

Quick Ratio

1.2337

Cash Ratio

0.6438

DSO

46.8111

DIO

55.9877

Op Cycle

102.7988

DPO

83.5269

CCC

19.2720

Gross Margin

0.7308

Op Margin

0.0863

Pretax Margin

0.0459

Net Margin

0.0398

Eff Tax Rate

0.1338

ROA

0.0425

ROE

0.1820

ROCE

0.1877

NI/EBT

0.8662

EBT/EBIT

0.5325

EBIT/Rev

0.0863

Debt Ratio

0.4596

D/E

1.9424

LT Debt/Cap

0.4741

Total Debt/Cap

0.6601

Int Coverage

2.8301

CF/Debt

0.3539

Equity Multi

4.2261

Rec Turnover

7.7973

Pay Turnover

4.3699

Inv Turnover

6.5193

FA Turnover

31.7093

Asset Turnover

1.0690

OCF/Share

0.6904

FCF/Share

0.6885

Cash/Share

2.0051

OCF/Sales

0.1522

FCF/OCF

0.9972

CF Coverage

0.3539

ST Coverage

0.6604

CapEx Coverage

362.4239

Div&CapEx Cov

362.4239

P/BV

2.6730

P/B

2.6730

P/S

0.6009

P/E

14.8699

P/FCF

3.9605

P/OCF

3.8888

P/CF

3.8888

PEG

0.0069

P/S

0.6009

EV Multiple

5.1197

P/FV

2.6730

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 15, 13:42 Adicet (ACET) Stock Rallies 130% in a Month: Here's Why Zacks Investment Research Jan 15, 13:42 Adicet (ACET) Stock Rallies 130% in a Month: Here's Why Zacks Investment Research Jan 15, 13:42 Adicet (ACET) Stock Rallies 130% in a Month: Here's Why Zacks Investment Research Dec 29, 12:51 Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition Zacks Investment Research Dec 26, 11:32 Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate Zacks Investment Research Dec 26, 10:10 Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag

Revenue Product Segmentation